Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer
Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the time to progressive disease in patients
treated with gemcitabine plus carboplatin versus carboplatin monotherapy. Patients will have
advanced epithelial ovarian cancer and have failed first-line platinum-containing therapy 6
months after treatment discontinuation.